1Wiley SR,Schooley K,Smolak PJ,et al.Identification and characterization of a new member of the TNF family that induce apoptosis.Immunity,1995,3(6):673.
2]Fisher MJ,Virmani AK,Wu L,et al.Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head neck cancer.Clin Cancer Res,2001,7:1688.
3Chen X,Kandasamy K,Srivastava P K.Differential roles of RelA and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis inducing ligand signaling.Cancer Res,2003,63:1059.
4Arts HJ,de Jong S,Hollema H,et al.Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.Gynecol Oncol,2004,92(3):794.
6Tomek S,Horak P,Pribill I,et al.Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.Gynecol Oncol,2004,94(1):107.
8Vignati S,Codegoni A,Polato E,et al.Trail activity in human ovarian cancer cells:potentiation of the action of cytotoxic drugs.Eur J Cancer,2002,38(1):177.
10Cuello M,Coats AO,Darko I,et al.N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.Cell Death Differ,2004,11(5):527.
7Cuello M, Ettenberg SA, Nau MM, et al. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells[ J]. Gynecol Oncol,2001,81(3) :380-390.
8Srivastava RK. Intracellular mechanisms of TRAIL and its role in cancer therapy [ J ]. Mol Cell Biol Res Commun, 2000, 4 : 67-75.
9Tomek S, Horak P, Pribill I, et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by cotreatment with cytotoxic drugs [J]. Gynecol Oncol, 2004, 94(1) :107-114.
10Kim K, Takimoto R, Dicker DT, et al. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines[J]. Int J Oncol,2001,18 ( 2 ) :241-247.
